Cargando…
Access to Novel Drugs for Non‐Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis
BACKGROUND: Treatment of non‐small cell lung cancer (NSCLC) improved substantially in the last decades. Novel targeted and immune‐oncologic drugs were introduced into routine treatment. Despite accelerated development and subsequent drug registrations by the European Medicinal Agency (EMA), novel dr...
Autores principales: | Cufer, Tanja, Ciuleanu, Tudor E., Berzinec, Peter, Galffy, Gabriela, Jakopovic, Marko, Jassem, Jacek, Jovanovic, Dragana, Mihaylova, Zhasmina, Ostoros, Gyula, Thallinger, Christiane, Zemanova, Milada, Zielinski, Christoph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066717/ https://www.ncbi.nlm.nih.gov/pubmed/32162818 http://dx.doi.org/10.1634/theoncologist.2019-0523 |
Ejemplares similares
-
Perspectives for Cancer Care and Research in Central and Eastern Europe
por: Zielinski, Christoph C., et al.
Publicado: (2023) -
Treatment Patterns and Real-world Evidence for Stage III Non-small Cell Lung Cancer in Central and Eastern Europe
por: Zemanova, Milada, et al.
Publicado: (2020) -
“What’s measured gets done”: a call for a European semester for cancer to improve cancer outcomes in Central and Southeastern Europe
por: Zielinski, Christoph, et al.
Publicado: (2023) -
Establishment of a virtual transborder tumor board for cancer patients in Central and Southeastern Europe: An initiative of the Central European Cooperative Oncology Group (CECOG)
por: Thallinger, Christiane, et al.
Publicado: (2022) -
Revising Incidence and Mortality of Lung Cancer in Central Europe: An Epidemiology Review From Hungary
por: Bogos, Krisztina, et al.
Publicado: (2019)